ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD

Phase 3positivetozorakimabPositive

AI Analysis

Summary

AstraZeneca presented Phase III data at ERS 2026 showing that tozorakimab, an IL-33 inhibitor, reduces mucus plug burden in COPD patients compared to placebo.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Tozorakimab reduces mucus plug burden in COPD patients compared to placebo

Importance:7/10

Sentiment:

0.70

Phase_3_dataCOPDIL-33_inhibitorconference_presentationERS_2026

Related Companies

$AZN

Read the original article

Published by Pharmaceutical Technology on September 8, 2026 2:15 PM

Read Original